Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Merck & Co. Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Loans payable and current portion of long-term debt 3,071 3,077 1,372 887 2,839 2,672 1,946 1,936 2,979 1,208 2,412 3,534 2,488 7,251 6,431 2,420 4,718 6,361 3,610 3,411 3,816 3,175
Trade accounts payable 3,519 3,514 3,922 3,509 3,442 3,680 4,264 3,371 3,482 3,715 4,609 3,366 3,897 4,034 4,594 3,744 3,448 3,572 3,738 3,198 3,142 3,018
Accrued and other current liabilities 14,712 14,102 15,766 14,840 13,747 13,000 14,159 14,222 13,501 14,051 13,859 14,214 12,888 11,911 13,053 11,690 11,182 10,932 12,549 11,768 11,054 10,081
Income taxes payable 2,777 2,398 2,649 1,981 1,489 1,872 1,986 1,698 1,438 1,571 1,224 954 971 1,490 1,575 984 1,266 1,033 736 873 634 807
Dividends payable 1,981 2,008 1,985 1,877 1,877 1,907 1,884 1,771 1,768 1,771 1,768 1,660 1,662 1,675 1,674 1,567 1,564 1,585 1,587 1,434 1,439 1,462
Current liabilities 26,060 25,099 25,694 23,094 23,394 23,131 24,239 22,998 23,168 22,316 23,872 23,728 21,906 26,361 27,327 20,405 22,178 23,483 22,220 20,684 20,085 18,543
Long-term debt, excluding current portion 34,717 31,142 33,683 33,972 34,072 28,074 28,745 28,482 28,684 30,586 30,690 22,907 24,033 24,002 25,360 26,321 26,156 21,637 22,736 22,677 22,771 22,721
Deferred income taxes 876 922 871 1,018 996 1,442 1,795 2,417 2,974 3,071 3,441 1,527 1,489 1,204 1,015 1,777 2,091 1,943 1,470 1,960 2,089 1,835
Other noncurrent liabilities 7,329 8,262 8,792 7,343 7,265 8,244 8,323 8,660 8,951 9,742 9,434 9,469 9,872 12,241 12,482 12,027 12,446 11,550 11,970 11,085 11,283 11,585
Noncurrent liabilities 42,922 40,326 43,346 42,333 42,333 37,760 38,863 39,559 40,609 43,399 43,565 33,903 35,394 37,447 38,857 40,125 40,693 35,130 36,176 35,722 36,143 36,141
Total liabilities 68,982 65,425 69,040 65,427 65,727 60,891 63,102 62,557 63,777 65,715 67,437 57,631 57,300 63,808 66,184 60,530 62,871 58,613 58,396 56,406 56,228 54,684
Common stock, $0.50 par value 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788 1,788
Other paid-in capital 44,362 44,598 44,509 44,358 44,219 44,467 44,379 44,243 44,115 44,275 44,238 44,149 44,039 39,613 39,588 39,489 39,373 39,697 39,660 39,561 39,484 38,768
Retained earnings 60,187 56,697 53,895 57,082 54,198 62,039 61,081 59,928 58,437 56,252 53,696 51,691 48,777 48,888 47,362 51,107 49,724 48,272 46,602 45,804 45,295 44,065
Accumulated other comprehensive loss (5,361) (5,274) (5,161) (4,916) (4,900) (4,883) (4,768) (4,743) (4,327) (4,369) (4,429) (4,590) (4,628) (6,622) (6,634) (6,383) (6,393) (6,391) (6,193) (5,390) (5,362) (5,346)
Treasury stock, at cost (57,394) (57,445) (57,450) (57,066) (56,612) (56,577) (56,489) (56,758) (56,770) (57,063) (57,109) (57,244) (56,682) (56,722) (56,787) (56,815) (56,850) (57,161) (55,950) (54,925) (53,570) (51,736)
Total Merck & Co., Inc. stockholders’ equity 43,582 40,364 37,581 41,246 38,693 46,834 45,991 44,458 43,243 40,883 38,184 35,794 33,294 26,945 25,317 29,186 27,642 26,205 25,907 26,838 27,635 27,539
Noncontrolling interests 66 60 54 54 49 71 67 66 75 70 73 69 94 94 87 84 102 95 94 87 102 131
Total equity 43,648 40,424 37,635 41,300 38,742 46,905 46,058 44,524 43,318 40,953 38,257 35,863 33,388 27,039 25,404 29,270 27,744 26,300 26,001 26,925 27,737 27,670
Total liabilities and equity 112,630 105,849 106,675 106,727 104,469 107,796 109,160 107,081 107,095 106,668 105,694 93,494 90,688 90,847 91,588 89,800 90,615 84,913 84,397 83,331 83,965 82,354

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Merck & Co. Inc. current liabilities decreased from Q4 2023 to Q1 2024 but then increased from Q1 2024 to Q2 2024 exceeding Q4 2023 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Merck & Co. Inc. noncurrent liabilities decreased from Q4 2023 to Q1 2024 but then increased from Q1 2024 to Q2 2024 not reaching Q4 2023 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Merck & Co. Inc. total liabilities decreased from Q4 2023 to Q1 2024 but then increased from Q1 2024 to Q2 2024 not reaching Q4 2023 level.
Total Merck & Co., Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Merck & Co. Inc. total Merck & Co., Inc. stockholders’ equity increased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.